Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cebranopadol - Tris Pharma

Next Previous
Drug Profile

Cebranopadol - Tris Pharma

Alternative Names: GRT-6005; PRK-101; TRN-228

Latest Information Update: 08 Sep 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Grunenthal
  • Developer Allergan; Grunenthal; Park Therapeutics; Tris Pharma
  • Class Cyclohexylamines; Drug withdrawal therapies; Indoles; Opioid analgesics; Small molecules; Spiro compounds
  • Mechanism of Action Nociceptin receptor agonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer pain

Highest Development Phases

  • Phase III Acute pain; Back pain
  • Phase II Cancer pain; Neuropathic pain
  • Phase I Pain; Substance-related disorders
  • Discontinued Diabetic neuropathies; Musculoskeletal pain; Postoperative pain

Most Recent Events

  • 06 Sep 2023 Updated efficacy data from a phase I trial in Substance-related disorders released by Tris Pharma
  • 28 Aug 2023 Tris Pharma plans a phase II trial for Opioid-related-disorders
  • 16 Dec 2022 Phase-III clinical trials in Acute pain in USA (PO) (Tris Pharma pipeline, December 2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top